Amylyx Pharmaceuticals, Inc. $AMLX Shares Sold by Cormorant Asset Management LP

Cormorant Asset Management LP decreased its holdings in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 20.0% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 400,000 shares of the company’s stock after selling 100,000 shares during the quarter. Cormorant Asset Management LP owned about 0.36% of Amylyx Pharmaceuticals worth $4,832,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. ACT Capital Management LLC acquired a new position in Amylyx Pharmaceuticals in the fourth quarter valued at $109,000. ADAR1 Capital Management LLC grew its holdings in Amylyx Pharmaceuticals by 2.8% in the 4th quarter. ADAR1 Capital Management LLC now owns 890,356 shares of the company’s stock valued at $10,756,000 after buying an additional 24,154 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Amylyx Pharmaceuticals by 7.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 107,548 shares of the company’s stock valued at $1,300,000 after acquiring an additional 7,103 shares during the last quarter. California State Teachers Retirement System lifted its holdings in shares of Amylyx Pharmaceuticals by 1,726.1% during the 4th quarter. California State Teachers Retirement System now owns 79,090 shares of the company’s stock worth $955,000 after acquiring an additional 74,759 shares during the period. Finally, Russell Investments Group Ltd. boosted its position in shares of Amylyx Pharmaceuticals by 18.1% in the fourth quarter. Russell Investments Group Ltd. now owns 65,438 shares of the company’s stock worth $790,000 after acquiring an additional 10,032 shares during the last quarter. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Amylyx Pharmaceuticals Stock Up 1.3%

NASDAQ AMLX opened at $15.25 on Thursday. The stock has a market cap of $1.70 billion, a PE ratio of -10.17 and a beta of -0.16. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $4.80 and a fifty-two week high of $18.60. The business has a 50 day moving average price of $15.15 and a two-hundred day moving average price of $14.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.03). Sell-side analysts anticipate that Amylyx Pharmaceuticals, Inc. will post -1.4 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on AMLX. Wall Street Zen downgraded shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Guggenheim raised their price target on shares of Amylyx Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Stifel Nicolaus assumed coverage on shares of Amylyx Pharmaceuticals in a research report on Tuesday, March 3rd. They set a “buy” rating and a $21.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research report on Friday, May 8th. Finally, Mizuho raised their target price on shares of Amylyx Pharmaceuticals from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.00.

Amylyx Pharmaceuticals Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.